Nanobodies inhibit SARS-CoV-2 infection

Australian researchers have identified neutralising nanobodies that block the SARS-CoV-2 virus from entering cells in preclinical models. The discovery paves the way for further investigations into nanobody-based treatments for COVID-19. Published in PNAS, the research is part of a consortium-led effort, bringing together the expertise of Australian academic leaders in infectious diseases and antibody therapeutics at WEHI, the Doherty Institute and the Kirby Institute.